Pfizer Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for PFIZER, and what generic alternatives to PFIZER drugs are available?
PFIZER has one hundred and eighty-nine approved drugs.
There are thirty-seven US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.
There are seven hundred and fifty-five patent family members on PFIZER drugs in sixty-six countries and two hundred and thirty-nine supplementary protection certificates in nineteen countries.
Summary for Pfizer
International Patents: | 755 |
US Patents: | 37 |
Tradenames: | 154 |
Ingredients: | 125 |
NDAs: | 189 |
Drug Master File Entries: | 3 |
Patent Litigation for Pfizer: | See patent lawsuits for Pfizer |
PTAB Cases with Pfizer as petitioner: | See PTAB cases with Pfizer as petitioner |
Drugs and US Patents for Pfizer
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | IBRANCE | palbociclib | CAPSULE;ORAL | 207103-002 | Feb 3, 2015 | RX | Yes | No | 10,723,730 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Pfizer | TETRACYN | procaine hydrochloride; tetracycline hydrochloride | INJECTABLE;INJECTION | 060285-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
Pfizer | ATARAX | hydroxyzine hydrochloride | TABLET;ORAL | 010392-006 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | |||||
Pfizer | PROVERA | medroxyprogesterone acetate | TABLET;ORAL | 011839-004 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | ||||
Pfizer | CIBINQO | abrocitinib | TABLET;ORAL | 213871-001 | Jan 14, 2022 | RX | Yes | No | 9,549,929 | See Plans and Pricing | See Plans and Pricing | ||||
Pfizer | IBRANCE | palbociclib | CAPSULE;ORAL | 207103-002 | Feb 3, 2015 | RX | Yes | No | RE47739 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pfizer
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pfizer | CAVERJECT | alprostadil | INJECTABLE;INJECTION | 020379-002 | Jul 6, 1995 | 4,127,118 | See Plans and Pricing |
Pfizer Pharms | REZULIN | troglitazone | TABLET;ORAL | 020720-003 | Aug 4, 1997 | 5,104,888 | See Plans and Pricing |
Pfizer | GLYSET | miglitol | TABLET;ORAL | 020682-001 | Dec 18, 1996 | 4,639,436 | See Plans and Pricing |
Pfizer | HEMABATE | carboprost tromethamine | INJECTABLE;INJECTION | 017989-001 | Approved Prior to Jan 1, 1982 | 3,728,382 | See Plans and Pricing |
Pfizer | GLUCOTROL XL | glipizide | TABLET, EXTENDED RELEASE;ORAL | 020329-001 | Apr 26, 1994 | 5,591,454 | See Plans and Pricing |
Pfizer Pharms | REZULIN | troglitazone | TABLET;ORAL | 020720-003 | Aug 4, 1997 | 4,572,912 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PFIZER drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 0.125 mg, 0.25 mg, and 0.5 mg | ➤ Subscribe | 2014-05-01 |
➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2005-12-21 |
➤ Subscribe | Injection | 2 mg/mL, 300 mL bag | ➤ Subscribe | 2009-09-01 |
➤ Subscribe | Tablets | 1 g | ➤ Subscribe | 2005-08-23 |
➤ Subscribe | Delayed-release Tablets | 75 mg/0.2 mg | ➤ Subscribe | 2008-11-28 |
➤ Subscribe | Extended-release Tablets | 4 mg and 8 mg | ➤ Subscribe | 2012-10-31 |
➤ Subscribe | Injection | 20 mg/mL, 2 mL and 5 mL vials | ➤ Subscribe | 2004-07-26 |
➤ Subscribe | Capsules | 5 mg and 10 mg | ➤ Subscribe | 2005-06-21 |
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2011-06-17 |
➤ Subscribe | Oral Suspension | 100 mg/5 mL | ➤ Subscribe | 2009-08-03 |
➤ Subscribe | Injection | 2 mg/mL, 100 mL bag | ➤ Subscribe | 2009-12-29 |
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Delayed-release Tablets | 50 mg/0.2 mg | ➤ Subscribe | 2009-06-29 |
➤ Subscribe | Extended-release Tablets | 11 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | ➤ Subscribe | 2005-02-07 |
➤ Subscribe | Capsules | 75 mg, 100 mg and 125 mg | ➤ Subscribe | 2019-02-04 |
International Patents for Pfizer Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Eurasian Patent Organization | 006227 | See Plans and Pricing |
Portugal | 2630146 | See Plans and Pricing |
Malaysia | 134818 | See Plans and Pricing |
Israel | 241400 | See Plans and Pricing |
Hungary | E037192 | See Plans and Pricing |
Cuba | 23220 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pfizer Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0253738 | C960002 | Netherlands | See Plans and Pricing | PRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127 |
1848414 | CA 2016 00033 | Denmark | See Plans and Pricing | PRODUCT NAME: OSIMERTINIB; REG. NO/DATE: EU/1/16/1086/001-0002 20160204 |
0328535 | 96C0021 | Belgium | See Plans and Pricing | PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209 |
0480717 | 98C0025 | Belgium | See Plans and Pricing | PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215 |
0402407 | 97C0005 | Belgium | See Plans and Pricing | PRODUCT NAME: ESTRADIOL HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: 298 IS 190 F 15 19960806; FIRST REGISTRATION: GB PL/0053/0241 19950711 |
1470124 | PA2017013,C1470124 | Lithuania | See Plans and Pricing | PRODUCT NAME: PALBOCIKLIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALU; REGISTRATION NO/DATE: EU/1/16/1147 20161109 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.